Effets indésirables immédiats des biothérapies dans les maladies inflammatoires chroniques de l’intestin (notice n° 664664)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02201cam a2200301 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193728.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Yzet, Clara |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Effets indésirables immédiats des biothérapies dans les maladies inflammatoires chroniques de l’intestin |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 5 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Biologics used for the treatment of Inflammatory Bowel Diseases are associated with a risk of immediate reaction (< 24h). Infliximab (IFX) was associated with a potentially serious infusion reaction risk. Subcutaneous biologics (adalimumab, golimumab and ustekinumab) may be responsible for local reaction, which exceptionally justifies stopping treatment. Uncertainties about the physiopathological mechanisms involved and the lack of interventional studies have led to different empirical protocols for their administration and their management. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les biothérapies utilisées pour le traitement des maladies inflammatoires chroniques de l’intestin sont associées à un risque de réactions immédiates (< 24 h). L’infliximab (IFX) a rapidement été associé à un risque de réaction à l’injection potentiellement grave. Les biothérapies sous-cutanées (adalimumab, golimumab et ustékinumab) peuvent être responsables de réactions locales, qui justifient exceptionnellement l’arrêt du traitement. Les incertitudes sur les mécanismes physiologlogiques engagés et le peu d’études d’intervention ont abouti à des protocoles d’administration et de prise en charge des réactions multiples et empiriques. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | réactions immédiates |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biothérapies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | réactions immédiates |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biothérapies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biologics |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immediate reaction |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biologics |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immediate reaction |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Loreau, Julien |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Brazier, Franck |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fumery, Mathurin |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 27 | 1 | 2020-01-01 | p. 30-35 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2020-1-page-30?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2020-1-page-30?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux